These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 12751376)
21. The use of early adjuvant aromatase inhibitor therapy: contributions from the BIG 1-98 letrozole trial. Forbes JF Semin Oncol; 2006 Apr; 33(2 Suppl 7):S2-7. PubMed ID: 16730270 [TBL] [Abstract][Full Text] [Related]
22. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer. Mouridsen H; Chaudri-Ross HA Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634 [TBL] [Abstract][Full Text] [Related]
23. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Therasse P; Palmer MJ; Pater JL N Engl J Med; 2003 Nov; 349(19):1793-802. PubMed ID: 14551341 [TBL] [Abstract][Full Text] [Related]
24. Early metabolic response to neoadjuvant letrozole, measured by FDG PET/CT, is correlated with a decrease in the Ki67 labeling index in patients with hormone receptor-positive primary breast cancer: a pilot study. Ueda S; Tsuda H; Saeki T; Omata J; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Moriya T; Yamamoto J Breast Cancer; 2011 Oct; 18(4):299-308. PubMed ID: 20617404 [TBL] [Abstract][Full Text] [Related]
26. Letrozole: a review of its use in postmenopausal women with breast cancer. Simpson D; Curran MP; Perry CM Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328 [TBL] [Abstract][Full Text] [Related]
27. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148 [TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer. Delea TE; Karnon J; Sofrygin O; Thomas SK; Papo NL; Barghout V Clin Breast Cancer; 2007 Jun; 7(8):608-18. PubMed ID: 17592673 [TBL] [Abstract][Full Text] [Related]
29. A randomised study of the effects of letrozole and anastrozole on oestrogen receptor positive breast cancers in postmenopausal women. Murray J; Young OE; Renshaw L; White S; Williams L; Evans DB; Thomas JS; Dowsett M; Dixon JM Breast Cancer Res Treat; 2009 Apr; 114(3):495-501. PubMed ID: 18438705 [TBL] [Abstract][Full Text] [Related]
30. Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. Goss PE; Ingle JN; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Tu D; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Pater JL; J Clin Oncol; 2007 May; 25(15):2006-11. PubMed ID: 17452676 [TBL] [Abstract][Full Text] [Related]
31. Letrozole in the extended adjuvant treatment of postmenopausal women with history of early-stage breast cancer who have completed 5 years of adjuvant tamoxifen. Mann BS; Johnson JR; Kelly R; Sridhara R; Williams G; Pazdur R Clin Cancer Res; 2005 Aug; 11(16):5671-7. PubMed ID: 16115902 [TBL] [Abstract][Full Text] [Related]
32. Superior efficacy of letrozole versus tamoxifen as first-line therapy. Buzdar AU J Clin Oncol; 2002 Feb; 20(3):876-8. PubMed ID: 11821477 [No Abstract] [Full Text] [Related]
33. Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective. Delea TE; El-Ouagari K; Karnon J; Sofrygin O Breast Cancer Res Treat; 2008 Apr; 108(3):375-87. PubMed ID: 17653859 [TBL] [Abstract][Full Text] [Related]
34. Letrozole in breast cancer. Shahab N N Engl J Med; 2004 Feb; 350(7):727-30; author reply 727-30. PubMed ID: 14971058 [No Abstract] [Full Text] [Related]
35. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women. Jahanzeb M Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537 [TBL] [Abstract][Full Text] [Related]
36. Letrozole: advancing hormone therapy in breast cancer. Lee RJ; Armstrong AC; Wardley AM Womens Health (Lond); 2012 Nov; 8(6):611-8. PubMed ID: 23181527 [TBL] [Abstract][Full Text] [Related]
37. Letrozole in advanced breast cancer: the PO25 trial. Mouridsen HT Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):19-29. PubMed ID: 17333340 [TBL] [Abstract][Full Text] [Related]
38. Role of endocrine therapy in the neoadjuvant surgical setting. Dixon JM Ann Surg Oncol; 2004 Jan; 11(1 Suppl):18S-23S. PubMed ID: 15015705 [TBL] [Abstract][Full Text] [Related]
39. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. Dowsett M; Ebbs SR; Dixon JM; Skene A; Griffith C; Boeddinghaus I; Salter J; Detre S; Hills M; Ashley S; Francis S; Walsh G; Smith IE J Clin Oncol; 2005 Apr; 23(11):2477-92. PubMed ID: 15767642 [TBL] [Abstract][Full Text] [Related]
40. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer. Barnadas A; Estévez LG; Lluch-Hernández A; Rodriguez-Lescure A; Rodriguez-Sanchez C; Sanchez-Rovira P Adv Ther; 2011 Dec; 28(12):1045-58. PubMed ID: 22068628 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]